OncoSec Medical (ONCS) Short Interest Ratio & Short Volume

Short interest is the volume of OncoSec Medical shares that have been sold short but have not yet been covered or closed out. As of May 31st, traders have sold 192,100 shares of ONCS short. 5.73% of OncoSec Medical's shares are currently sold short. Learn More on OncoSec Medical's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.73% of OncoSec Medical's floating shares are currently sold short.

OncoSec Medical saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 192,100 shares, an increase of 291.2% from the previous total of 49,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

OncoSec Medical currently has issued a total of 4,550,000 shares. Some of OncoSec Medical's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. OncoSec Medical currently has a public float of 3,350,000 shares.

5.73% of OncoSec Medical's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to OncoSec Medical: Eiger BioPharmaceuticals, Inc. (2.27%), Comera Life Sciences Holdings, Inc. (2.38%), Sunshine Biopharma, Inc. (7.32%), GRI Bio, Inc. (0.61%), TC Biopharm (Holdings) Plc (34.94%), Panbela Therapeutics, Inc. (2.36%), Biodexa Pharmaceuticals Plc (14.70%), Virax Biolabs Group Limited (0.69%), NeuBase Therapeutics, Inc. (0.81%), 180 Life Sciences Corp. (3.30%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.00 billion), Suncor Energy Inc. ($2.98 billion), Charter Communications, Inc. ($2.88 billion), Occidental Petroleum Co. ($2.79 billion), Moderna, Inc. ($2.39 billion), Snowflake Inc. ($2.38 billion), Coinbase Global, Inc. ($2.22 billion), Palantir Technologies Inc. ($2.18 billion), T. Rowe Price Group, Inc. ($2.03 billion), and Verisk Analytics, Inc. ($2.02 billion). View all of the most shorted stocks.

Short selling ONCS is an investing strategy that aims to generate trading profit from OncoSec Medical as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for OncoSec Medical occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ONCS, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ONCS, twice per month. The most recent reporting period available is May, 31 2023.